Denali Therapeutics (NASDAQ:DNLI) Insider Alexander Schuth Sells 2,857 Shares

Denali Therapeutics Inc. (NASDAQ:DNLI) insider Alexander Schuth sold 2,857 shares of Denali Therapeutics stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total transaction of $71,624.99. Following the transaction, the insider owned 281,763 shares of the company’s stock, valued at $7,063,798.41. This represents a 1.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Denali Therapeutics Trading Down 1.8%

NASDAQ:DNLI opened at $24.82 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.37 and a quick ratio of 8.32. Denali Therapeutics Inc. has a one year low of $12.58 and a one year high of $27.30. The company has a market cap of $3.97 billion, a PE ratio of -8.74 and a beta of 1.01. The firm has a 50-day moving average of $23.94 and a 200-day moving average of $21.46.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The company had revenue of $3.60 million for the quarter, compared to analyst estimates of $2.15 million. During the same quarter last year, the firm posted ($0.72) earnings per share. As a group, equities research analysts expect that Denali Therapeutics Inc. will post -2.6 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Sanford C. Bernstein reaffirmed a “hold” rating on shares of Denali Therapeutics in a research report on Monday, June 22nd. Robert W. Baird set a $34.00 price objective on Denali Therapeutics in a research note on Friday, August 7th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Denali Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Friday, July 17th. Finally, UBS Group increased their target price on shares of Denali Therapeutics from $25.00 to $34.00 and gave the company a “buy” rating in a report on Friday, August 7th. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.92.

Institutional Trading of Denali Therapeutics

Hedge funds have recently bought and sold shares of the business. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Denali Therapeutics in the second quarter worth $477,000. Elevation Point Wealth Partners LLC bought a new position in Denali Therapeutics in the 2nd quarter valued at $215,000. Ieq Capital LLC purchased a new stake in shares of Denali Therapeutics during the 2nd quarter valued at $519,000. Allworth Financial LP purchased a new stake in shares of Denali Therapeutics during the 2nd quarter valued at $47,000. Finally, B. Metzler seel. Sohn & Co. AG bought a new stake in shares of Denali Therapeutics during the 2nd quarter worth $2,888,000. 92.92% of the stock is currently owned by institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.